{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:33:32Z","timestamp":1772447612197,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Aichi Medical University and Novartis Pharma K.K.","award":["3310198"],"award-info":[{"award-number":["3310198"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.intimp.2016.07.019","type":"journal-article","created":{"date-parts":[[2016,8,3]],"date-time":"2016-08-03T07:37:37Z","timestamp":1470209857000},"page":"192-198","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["5\u00adyear follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment"],"prefix":"10.1016","volume":"39","author":[{"given":"Takahisa","family":"Hiramitsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8446-7841","authenticated-orcid":false,"given":"Manabu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Futamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Tsujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1620-6962","authenticated-orcid":false,"given":"Shunji","family":"Narumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Watarai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenta","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuharu","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2016.07.019_bb0005","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2016.07.019_bb0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","article-title":"Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2016.07.019_bb0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineulin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomized, controlled trial","volume":"377","author":"Budde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2016.07.019_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized zeus study","volume":"15","author":"Budde","year":"2015","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2016.07.019_bb0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ctr.12127","article-title":"Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen","volume":"27","author":"Kamar","year":"2013","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.intimp.2016.07.019_bb0030","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2016.07.019_bb0035","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients","volume":"5","author":"Vitko","year":"2005","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2016.07.019_bb0040","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"Tedesco","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2016.07.019_bb0045","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24months in renal transplantation","volume":"15","author":"Cibrik","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2016.07.019_bb0050","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2047-1440-2-14","article-title":"Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results","volume":"2","author":"Takahashi","year":"2013","journal-title":"Transp. Res."},{"key":"10.1016\/j.intimp.2016.07.019_bb0055","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/ajt.13649","article-title":"Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation","volume":"16","author":"H\u00f6cker","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2016.07.019_bb0060","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/TP.0b013e31824810e6","article-title":"Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients","volume":"15","author":"Nashan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2016.07.019_bb0065","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/TP.0b013e3181952623","article-title":"Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review","volume":"87","author":"Knight","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.intimp.2016.07.019_bb0070","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.transproceed.2011.11.055","article-title":"Everolimus with reduced-dose cyclosporine versus full-dose cyclosporine and mycophenolate in de novo renal transplant patients: a 2-year single-center experience","volume":"44","author":"Santos","year":"2012","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.intimp.2016.07.019_bb0075","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1600-6143.2012.04334.x","article-title":"The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes","volume":"13","author":"Wiseman","year":"2013","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2016.07.019_bb0080","doi-asserted-by":"crossref","first-page":"515","DOI":"10.5301\/JN.2011.6235","article-title":"Low-grade albuminuria reduction with angiotensin II type 1 receptor blocker in renal transplant recipients","volume":"24","author":"Uchida","year":"2011","journal-title":"J. Nephrol."},{"key":"10.1016\/j.intimp.2016.07.019_bb0085","first-page":"433","article-title":"Effects of angiotensin II receptor blocker on proteinuria in renal transplant recipients","volume":"18","author":"Tanji","year":"2004","journal-title":"In Vivo"},{"issue":"Suppl. 3","key":"10.1016\/j.intimp.2016.07.019_bb0090","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/nep.12247","article-title":"De novo proteinuria with pathological evidence of glomerulonephritis after everolimus induction","volume":"19","author":"Miura","year":"2014","journal-title":"Nephrology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576916302909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576916302909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T14:26:31Z","timestamp":1536503191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576916302909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":18,"alternative-id":["S1567576916302909"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2016.07.019","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5\u00adyear follow-up of a randomized clinical study comparing everolimus plus reduced-dose cyclosporine with mycophenolate mofetil plus standard-dose cyclosporine in de novo kidney transplantation: Retrospective single center assessment","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2016.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}